G-code: Procedures and professional services (temporary) Procedures and professional services (temporary)
2,011 codes
Billing context
G-codes are temporary codes for professional services and procedures that would otherwise be coded in CPT.
| Code | Long descriptor | Payment limit (Q4 2026) | Added | Status |
|---|---|---|---|---|
| G9773 | At least 1 body temperature measurement equal to or greater than 35.5 degrees celsius (or 95.9 degrees fahrenheit) not achieved within the 30 minutes immediately before or 15 minutes immediately after anesthesia end time, reason not given | — | Jan 1, 2017 | Active |
| G9774 | Patients who have had a hysterectomy | — | Jan 1, 2017 | Ended Dec 31, 2022 |
| G9775 | Patient received at least 2 prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively | — | Jan 1, 2017 | Active |
| G9776 | Documentation of medical reason for not receiving at least 2 prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively (e.g., intolerance or other medical reason) | — | Jan 1, 2017 | Active |
| G9777 | Patient did not receive at least 2 prophylactic pharmacologic anti-emetic agents of different classes preoperatively and/or intraoperatively | — | Jan 1, 2017 | Active |
| G9778 | Patients who have a diagnosis of pregnancy at any time during the measurement period | — | Jan 1, 2017 | Ended Dec 31, 2022 |
| G9779 | Patients who are breastfeeding at any time during the performance period | — | Jan 1, 2017 | Active |
| G9780 | Patients who have a diagnosis of rhabdomyolysis at any time during the performance period | — | Jan 1, 2017 | Active |
| G9781 | Documentation of medical reason(s) for not currently being a statin therapy user or receiving an order (prescription) for statin therapy (e.g., patients with statin-associated muscle symptoms or an allergy to statin medication therapy, patients who are receiving palliative or hospice care, patients with active liver disease or hepatic disease or insufficiency, patients with end stage renal disease [esrd], or other medical reasons) | — | Jan 1, 2017 | Active |
| G9782 | History of or active diagnosis of familial hypercholesterolemia | — | Jan 1, 2017 | Active |
| G9783 | Documentation of patients with diabetes who have a most recent fasting or direct ldl- c laboratory test result < 70 mg/dl and are not taking statin therapy | — | Jan 1, 2017 | Ended Dec 31, 2021 |
| G9784 | Pathologists/dermatopathologists providing a second opinion on a biopsy | — | Jan 1, 2017 | Active |
| G9785 | Pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) sent from the pathologist/ dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist | — | Jan 1, 2017 | Active |
| G9786 | Pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) was not sent from the pathologist/ dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist | — | Jan 1, 2017 | Active |
| G9787 | Patient alive as of the last day of the measurement year | — | Jan 1, 2017 | Active |
| G9788 | Most recent bp is less than or equal to 130/80 mm hg | — | Jan 1, 2017 | Active |
| G9789 | Blood pressure recorded during inpatient stays, emergency room visits, or urgent care visits | — | Jan 1, 2017 | Active |
| G9790 | Most recent bp is greater than 130/80 mm hg, or blood pressure not documented | — | Jan 1, 2017 | Active |
| G9791 | Most recent tobacco status is tobacco free | — | Jan 1, 2017 | Active |
| G9792 | Most recent tobacco status is not tobacco free | — | Jan 1, 2017 | Active |
| G9793 | Patient is currently on a daily aspirin or other antiplatelet | — | Jan 1, 2017 | Active |
| G9794 | Documentation of medical reason(s) for not on a daily aspirin or other antiplatelet (e.g., history of gastrointestinal bleed, intra-cranial bleed, idiopathic thrombocytopenic purpura (itp), gastric bypass or documentation of active anticoagulant use during the measurement period) | — | Jan 1, 2017 | Active |
| G9795 | Patient is not currently on a daily aspirin or other antiplatelet | — | Jan 1, 2017 | Active |
| G9796 | Patient is currently on a high intensity statin therapy | — | Jan 1, 2017 | Active |
| G9797 | Patient is not on a high intensity statin therapy | — | Jan 1, 2017 | Active |
| G9798 | Discharge(s) for ami between july 1 of the year prior measurement period to june 30 of the measurement period | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9799 | Patients with a medication dispensing event indicator of a history of asthma any time during the patient's history through the end of the measure period | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9800 | Patients who are identified as having an intolerance or allergy to beta-blocker therapy | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9801 | Hospitalizations in which the patient was transferred directly to a non-acute care facility for any diagnosis | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9802 | Patients who use hospice services any time during the measurement period | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9803 | Patient prescribed at least a 135 day treatment within the 180-day measurement interval with beta-blockers post-discharge for ami | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9804 | Patient was not prescribed at least a 135 day treatment within the 180-day measurement interval with beta-blockers post-discharge for ami | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9805 | Patients who use hospice services any time during the measurement period | — | Jan 1, 2017 | Active |
| G9806 | Patients who received cervical cytology or an hpv test | — | Jan 1, 2017 | Active |
| G9807 | Patients who did not receive cervical cytology or an hpv test | — | Jan 1, 2017 | Active |
| G9808 | Any patients who had no asthma controller medications dispensed during the measurement year | — | Jan 1, 2017 | Ended Dec 31, 2022 |
| G9809 | Patients who use hospice services any time during the measurement period | — | Jan 1, 2017 | Ended Dec 31, 2022 |
| G9810 | Patient achieved a pdc of at least 75% for their asthma controller medication | — | Jan 1, 2017 | Ended Dec 31, 2022 |
| G9811 | Patient did not achieve a pdc of at least 75% for their asthma controller medication | — | Jan 1, 2017 | Ended Dec 31, 2022 |
| G9812 | Patient died including all deaths occurring during the hospitalization in which the operation was performed, even if after 30 days, and those deaths occurring after discharge from the hospital, but within 30 days of the procedure | — | Jan 1, 2017 | Active |
| G9813 | Patient did not die within 30 days of the procedure or during the index hospitalization | — | Jan 1, 2017 | Active |
| G9814 | Death occurring during the index acute care hospitalization | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9815 | Death did not occur during the index acute care hospitalization | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9816 | Death occurring after discharge from the hospital but within 30 days post procedure | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9817 | Death did not occur after discharge from the hospital within 30 days post procedure | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9818 | Documentation of sexual activity | — | Jan 1, 2017 | Active |
| G9819 | Patients who use hospice services any time during the measurement period | — | Jan 1, 2017 | Active |
| G9820 | Documentation of a chlamydia screening test with proper follow-up | — | Jan 1, 2017 | Active |
| G9821 | No documentation of a chlamydia screening test with proper follow-up | — | Jan 1, 2017 | Active |
| G9822 | Patients who had an endometrial ablation procedure during the 12 months prior to the index date (exclusive of the index date) | — | Jan 1, 2017 | Active |
| G9823 | Endometrial sampling or hysteroscopy with biopsy and results documented during the 12 months prior to the index date (exclusive of the index date) of the endometrial ablation | — | Jan 1, 2017 | Active |
| G9824 | Endometrial sampling or hysteroscopy with biopsy and results not documented during the 12 months prior to the index date (exclusive of the index date) of the endometrial ablation | — | Jan 1, 2017 | Active |
| G9825 | Her-2/neu negative or undocumented/unknown | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9826 | Patient transferred to practice after initiation of chemotherapy | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9827 | Her2-targeted therapies not administered during the initial course of treatment | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9828 | Her2-targeted therapies administered during the initial course of treatment | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9829 | Breast adjuvant chemotherapy administered | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9830 | Her-2/neu positive | — | Jan 1, 2017 | Active |
| G9831 | Ajcc stage at breast cancer diagnosis = ii or iii | — | Jan 1, 2017 | Active |
| G9832 | Ajcc stage at breast cancer diagnosis = i (ia or ib) and t-stage at breast cancer diagnosis = t1c | — | Jan 1, 2017 | Active |
| G9833 | Patient transfer to practice after initiation of chemotherapy | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9834 | Patient has metastatic disease at diagnosis | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9835 | Trastuzumab administered within 12 months of diagnosis | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9836 | Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant chemotherapy or radiation not complete) | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9837 | Trastuzumab not administered within 12 months of diagnosis | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9838 | Patient has metastatic disease at diagnosis | — | Jan 1, 2017 | Active |
| G9839 | Anti-egfr monoclonal antibody therapy | — | Jan 1, 2017 | Active |
| G9840 | Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moab | — | Jan 1, 2017 | Active |
| G9841 | Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moab | — | Jan 1, 2017 | Active |
| G9842 | Patient has metastatic disease at diagnosis | — | Jan 1, 2017 | Active |
| G9843 | Ras (kras or nras) gene mutation | — | Jan 1, 2017 | Active |
| G9844 | Patient did not receive anti-egfr monoclonal antibody therapy | — | Jan 1, 2017 | Active |
| G9845 | Patient received anti-egfr monoclonal antibody therapy | — | Jan 1, 2017 | Active |
| G9846 | Patients who died from cancer | — | Jan 1, 2017 | Active |
| G9847 | Patient received systemic cancer-directed therapy in the last 14 days of life | — | Jan 1, 2017 | Active |
| G9848 | Patient did not receive systemic cancer-directed therapy in the last 14 days of life | — | Jan 1, 2017 | Active |
| G9849 | Patients who died from cancer | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9850 | Patient had more than one emergency department visit in the last 30 days of life | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9851 | Patient had one or less emergency department visits in the last 30 days of life | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9852 | Patients who died from cancer | — | Jan 1, 2017 | Ended Dec 31, 2023 |
| G9853 | Patient admitted to the icu in the last 30 days of life | — | Jan 1, 2017 | Ended Dec 31, 2023 |
| G9854 | Patient was not admitted to the icu in the last 30 days of life | — | Jan 1, 2017 | Ended Dec 31, 2023 |
| G9855 | Patients who died from cancer | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9856 | Patient was not admitted to hospice | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9857 | Patient admitted to hospice | — | Jan 1, 2017 | Ended Dec 31, 2020 |
| G9858 | Patient enrolled in hospice | — | Jan 1, 2017 | Active |
| G9859 | Patients who died from cancer | — | Jan 1, 2017 | Active |
| G9860 | Patient spent less than three days in hospice care | — | Jan 1, 2017 | Active |
| G9861 | Patient spent greater than or equal to three days in hospice care | — | Jan 1, 2017 | Active |
| G9862 | Documentation of medical reason(s) for not recommending at least a 10 year follow-up interval (e.g., inadequate prep, familial or personal history of colonic polyps, patient had no adenoma and age is = 66 years old, or life expectancy < 10 years old, other medical reasons) | — | Jan 1, 2017 | Active |
| G9868 | Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, less than 10 minutes | — | Jan 1, 2018 | Active |
| G9869 | Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, 10-20 minutes | — | Jan 1, 2018 | Active |
| G9870 | Receipt and analysis of remote, asynchronous images for dermatologic and/or ophthalmologic evaluation, for use only in a medicare-approved cmmi model, more than 20 minutes | — | Jan 1, 2018 | Active |
| G9871 | Behavioral counseling for diabetes prevention, online, 60 minutes | — | Jan 1, 2026 | Active |
| G9873 | First medicare diabetes prevention program (mdpp) core session was attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions | — | Apr 1, 2018 | Active |
| G9874 | Four total medicare diabetes prevention program (mdpp) core sessions were attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions | — | Apr 1, 2018 | Active |
| G9875 | Nine total medicare diabetes prevention program (mdpp) core sessions were attended by an mdpp beneficiary under the mdpp expanded model (em). a core session is an mdpp service that: (1) is furnished by an mdpp supplier during months 1 through 6 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for core sessions | — | Apr 1, 2018 | Active |
| G9876 | Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 7-9 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary did not achieve at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 7-9 | — | Apr 1, 2018 | Active |
| G9877 | Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 10-12 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions. the beneficiary did not achieve at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 10-12 | — | Apr 1, 2018 | Active |
| G9878 | Two medicare diabetes prevention program (mdpp) core maintenance sessions (ms) were attended by an mdpp beneficiary in months (mo) 7-9 under the mdpp expanded model (em). a core maintenance session is an mdpp service that: (1) is furnished by an mdpp supplier during months 7 through 12 of the mdpp services period; (2) is approximately 1 hour in length; and (3) adheres to a cdc-approved dpp curriculum for maintenance sessions.the beneficiary achieved at least 5% weight loss (wl) from his/her baseline weight, as measured by at least one in-person weight measurement at a core maintenance session in months 7-9 | — | Apr 1, 2018 | Active |